

UC San Diego
Jacobs School of Engineering

Shicheng Guo <shg047@eng.ucsd.edu>

Manuscript ID LCNV-2015-0175 is now in your Reviewer Centre - Cancer Investigation

1 message

GLyman@fhcrc.org <GLyman@fhcrc.org>
To: scguo@ucsd.edu

Mon, Jun 8, 2015 at 12:20 PM

08-Jun-2015

Dear Dr shicheng guo:

Thank you for agreeing to review the above manuscript, entitled "A multi-center phase II study of nintedanib as second-line therapy for patients with advanced non-small-cell lung cancer in China" for Cancer Investigation.

To access the manuscript and complete your review, please click on the following link:

https://mc.manuscriptcentral.com/lcnv?URL_MASK=9d92a09d88d542a0aec7dc0f2cbc1dd3

On the review page, there is a space for "Comments to Editor" and a space for "Comments to the Author."

Please be sure to put your comments to the author in the appropriate space.

If you wish to view the manuscript and the review form simultaneously, click on the HTML or PDF icons – the manuscript will open in a new window. Leave the new window open, switch back to the main window, and open the score sheet by clicking on the Score Sheet tab. Follow the instructions for reviewers provided in the Manuscript Central site.

I strongly encourage you to elaborate on your review in the space provided. Your specific comments will offer valuable feedback to improve future work. It is essential that you click the "Save" button if you wish to exit the review before you submit it to the Editor. Otherwise, none of the information that you have entered will be saved in the system. When you have completed your review and are ready to submit it to the Editor, click on "Submit."

Please note, to log into your account on the Manuscript Central site at a later date, your case-sensitive USER ID is scguo@ucsd.edu. Your Password: 8hxqmct3.

Thank you for evaluating this manuscript.

Sincerely,
Professor Lyman
Cancer Investigation Editorial Office
GLyman@FHCRC.ORG

P.S. Please may we remind you that agreeing to review an article for this Journal implies that you as the reviewer will adhere to the accepted ethical standards of scientific, medical and academic publishing. Material submitted for peer review is a privileged communication that should be treated in confidence. Material under review should not be shared or discussed with anyone outside the designated review process, unless approved by the editor. All communications relating to the paper in review should also be treated in confidence. Any breach of confidentiality in the review process is taken seriously by the journal and will be investigated according to the advice of COPE (<http://publicationethics.org>). Any conflict of interest, suspicion of duplicate publication, fabrication of data, plagiarism or other ethical concerns must immediately be reported to the Editor.

By agreeing to review this manuscript, you are stating that you are the person completing this review. If you wish to collaborate with a colleague and/or trainee to perform this review, or wish to assign this review to a trainee for completion under your guidance, please contact the Editor for permission before sharing the manuscript. If the Editor agrees please provide the name, affiliation and e-mail address for the trainee/colleague so he or she may be assigned as a reviewer directly.

If you have any conflict of interest (for example, collaborate with the author(s) or are currently working on a similar study), please decline to review this manuscript and, if possible, suggest appropriate alternate reviewers.